季度报告披露
Search documents
山东东宏管业股份有限公司 2025年第三季度报告
Zheng Quan Ri Bao· 2025-10-28 23:35
Core Points - The company has ensured the authenticity, accuracy, and completeness of the quarterly report, taking legal responsibility for any false records or significant omissions [2][7][27] - The board of directors approved the third-quarter report for 2025 during the meeting held on October 28, 2025, with unanimous support from all attending members [8][9] - The company has decided to make provisions for impairment, which aligns with accounting standards and reflects the financial status and operational results more accurately [13][14] - Several internal governance systems have been revised to enhance operational standards and compliance with legal regulations [16][18][22] Financial Data - The financial statements for the third quarter of 2025 have not been audited [3][6] - The report period refers to the three months from the beginning to the end of the quarter [3] Shareholder Information - There are no changes in the major shareholders or the status of shares available for trading compared to the previous period [4] Other Important Information - The company has not identified any significant operational issues during the reporting period that require investor attention [5]
深圳市易瑞生物技术股份有限公司2025年第三季度报告
Shang Hai Zheng Quan Bao· 2025-10-27 22:11
Core Points - The company ensures that the content of the quarterly report is true, accurate, and complete, with no false records or misleading statements [2][8] - The third-quarter financial report has not been audited [3][7] Financial Data - The company does not require retrospective adjustments or restatements of previous annual accounting data [3] - There are no non-recurring profit and loss items applicable for the reporting period [3][4] - The company confirms that there are no changes in major accounting data and financial indicators that require explanation [5] Shareholder Information - The total number of ordinary shareholders and the number of preferred shareholders have changed due to stock issuance and other reasons [5] - There are no changes in the top ten shareholders or the top ten unrestricted circulating shareholders due to stock lending activities [5][6] Board Meeting - The company's board meeting was held on October 27, 2025, with all seven directors present, complying with legal and regulatory requirements [9][10] - The board approved the third-quarter report and the appointment of a new member to the strategic committee [10][11]
安徽宏宇五洲医疗器械股份有限公司 2025年第一季度报告
Zheng Quan Ri Bao· 2025-04-25 23:37
Group 1 - The company guarantees the authenticity, accuracy, and completeness of the information disclosed in the quarterly report, with no false records, misleading statements, or significant omissions [1][2][8] - The board of directors and supervisory board confirm the quarterly report's compliance with legal and regulatory requirements, reflecting the company's financial status, operating results, and cash flow accurately [10][18] - The first quarter report has not been audited [7][11] Group 2 - The third board of directors' eighth meeting was held on April 25, 2025, with all seven directors present, complying with legal and regulatory requirements [9] - The meeting approved the proposal regarding the first quarter report, confirming its adherence to relevant regulations and accurate reflection of the company's financial situation [10][18] - The voting results for the board meeting were unanimous, with all votes in favor [12] Group 3 - The company will hold the 2024 annual shareholders' meeting on May 15, 2025, using a combination of on-site and online voting [22][24] - The meeting's legal compliance has been confirmed by the board of directors, and all shareholders registered by May 9, 2025, are eligible to attend [23][26] - The meeting will address various proposals, including the independent directors' performance reports [30][32]